Zimbabwe has turned down a major American health deal worth 367 million US dollars (£272m) over five years due to Washington's request for sensitive information.
This move became public following a internal memorandum from December was disclosed, indicating that President Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesperson has since explained that the United States was requesting biological samples for scientific study and profit while was unwilling to share the resulting advantages from any future treatments.
"We must now begin the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for more negotiations to find a agreement agreeable to both sides so the country's critical HIV treatment initiative can continue.
Broader Implications
This development follows a comparable situation in neighbouring Kenya, where a high court suspended a related health funding agreement following concerns were raised about the security of citizens' health data.
After returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing government-to-government deals to boost openness and responsibility.
According to reports, Sixteen African countries have so far signed similar agreements, representing more than $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million presently on HIV treatment through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Effectively, our country would provide the basic resources for medical research without any certainty that the end products would be accessible to our population should a new health crisis arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were disrupting frameworks already set up via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to manage future pandemics.
"This mechanism is designed to guarantee that when a nation provides its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent co-operation might be arranged in a manner that respects the independence and dignity of each country."
Medical Community Reaction
A leading public health body expressed it understood the official position, but suggested that negotiations must proceed considering much of the nation's HIV programmes relied on external financing.
"In cases where technical issues arise, including those relating to information security or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal emphasises the complex tensions between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.